Quantbot Technologies LP C4 Therapeutics, Inc. Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$5.3 - $11.0 $54,590 - $113,300	10,300 New	10,300 $84,000
Q3 2023 Nov 07, 2023	SELL	$1.81 - $3.89 $17,236 - $37,044	-9,523 Reduced 62.16%	5,796 $10,000
Q2 2023 Aug 08, 2023	BUY	$2.75 - $3.77 $32,450 - $44,486	11,800 Added 335.32%	15,319 $42,000
Q1 2023 May 12, 2023	SELL	$3.1 - $9.02 $4,879 - $14,197	-1,574 Reduced 30.91%	3,519 $11,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $27,604 - $52,152	5,093 New	5,093 $30,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $33,983 - $56,490	-1,700 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$29.39 - $46.86 $58,780 - $93,720	-2,000 Reduced 54.05%	1,700 $54,000
Q3 2021 Nov 09, 2021	BUY	$35.91 - $50.5 $132,867 - $186,850	3,700 New	3,700 $165,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.